PI-@ at @ mg/d delayed the onset and frequency of HCC recurrence , and provided a clinically significant survival advantage for up to @ years after treatment compared with those of the control group : ( @ ) the recurrence-free rate increased from @ % to @ % , and ( @ ) time to recurrence at the @th percentile was postponed by @ % .